LQDA - Liquidia Corporation Forward P/S Multiple

Corporate company logo of Liquidia Corporation (LQDA)

Logistics optimization for inhalation agents targeting rare pathologies provides Liquidia Corporation (LQDA) with high margins and stable sales. The expected revenue multiple visualizes this trend, where the parameter value equals 8.30. While its status as an innovator in pulmonary hypertension therapy strengthens the brand image, the ultimate success of the business relies heavily on the outcomes of patent litigation and regulatory timelines.

LQDA Liquidia Corp: Projected Price to Revenue in the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Liquidia Corporation

- market price and analyst price targets:
Fundamental company valuation:Liquidia Inc. LQDA
Product sample of Liquidia Inc.

Amid prolonged legal disputes regarding Liquidia Corporation (LQDA) and its product launch, the projected P/S valuation reflects the level of investor confidence in the success of the commercial rollout. This indicator compares current market capitalization with expected sales volume, determining whether the scalability premium is overvalued relative to real future revenue prospects.

Analysis of competing companies

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Price-to-Projected Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP